Between the Lines™ Podcast: Incorporating Real-World Evidence into Clinical Decisions in NSCLC
Lyudmila Bazhenova, MD, and Federico Albrecht, MD, detailed the importance of using real-world evidence to inform treatment for patients with EGFR-mutated non–small cell lung cancer.
As part of its Between the Lines™ video series, CancerNetwork® spoke with Lyudmila Bazhenova, MD, a professor of medicine at the University of California San Diego Health, and Federico Albrecht, MD, an oncologist/hematologist at Miami Cancer Institute, Baptist Health South Florida, about when and how to use real-world evidence when making treatment decisions for patients with EGFR-mutated non–small cell lung cancer (NSCLC).
In the video series, Bazhenova and Albrecht discussed the following:
- Presentation: Benefits and Limitations of RWE: Lessons From EGFR Mutation-Positive NSCLC
- EGFR-Mutant NSCLC: Addressing Gaps When Collecting Data
- Experts in Treating EGFR-Positive NSCLC Compare Randomized Trials and Real-World Studies
- EGFR-Mutant NSCLC: Incorporating RWE Into Treatment Decisions
- Referring to Real-World Evidence When Managing EGFR-Mutant NSCLC
- Using Various Sources of Information to Guide Management of EGFR-Mutated NSCLC
- Increasing Rates of Real-World Studies in EGFR-Mutated NSCLC
To watch more videos in CancerNetwork®’s Between the Lines™ series, visit cancernetwork.com/between-the-lines.
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.
These data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens.
